#ECTRIMS2019 – Ofatumumab Part of ‘Magnificent Success Story’ for MS, ASCLEPIOS Trial Investigator Says
Ofatumumab, an investigational B-cell therapy being developed by Novartis, demonstrated encouraging results in lowering relapse rates and active brain lesions in people with relapsing multiple sclerosis (MS) enrolled in the ASCLEPIOS trials. For Stephen L. Hauser, MD, an investigator in the ASCLEPIOS trials, these results represent a…